Axovant Sciences (AXON) Shares Gap Up to $1.12

Shares of Axovant Sciences Ltd (NASDAQ:AXON) gapped up before the market opened on Tuesday . The stock had previously closed at $1.11, but opened at $1.12. Axovant Sciences shares last traded at $1.06, with a volume of 29896 shares traded.

Several brokerages recently issued reports on AXON. ValuEngine lowered Axovant Sciences from a “buy” rating to a “hold” rating in a report on Wednesday, January 2nd. Zacks Investment Research lowered Axovant Sciences from a “buy” rating to a “hold” rating in a report on Tuesday, November 13th. Oppenheimer reiterated a “hold” rating on shares of Axovant Sciences in a report on Sunday, November 11th. BidaskClub lowered Axovant Sciences from a “sell” rating to a “strong sell” rating in a report on Thursday, November 8th. Finally, Cowen reissued a “hold” rating on shares of Axovant Sciences in a research report on Thursday, September 20th. One equities research analyst has rated the stock with a sell rating, four have given a hold rating and three have assigned a buy rating to the stock. The company presently has a consensus rating of “Hold” and a consensus price target of $3.81.

The company has a current ratio of 1.97, a quick ratio of 1.97 and a debt-to-equity ratio of 1.68. The stock has a market capitalization of $132.06 million, a P/E ratio of -0.55 and a beta of 1.22.

Axovant Sciences (NASDAQ:AXON) last posted its earnings results on Wednesday, November 7th. The biotechnology company reported ($0.28) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.38) by $0.10. As a group, equities research analysts anticipate that Axovant Sciences Ltd will post -1.25 EPS for the current fiscal year.

In other Axovant Sciences news, major shareholder Svf Investments (Uk) Ltd bought 10,000,000 shares of the stock in a transaction on Tuesday, December 18th. The shares were purchased at an average cost of $1.00 per share, with a total value of $10,000,000.00. Following the completion of the transaction, the insider now directly owns 99,285,714 shares of the company’s stock, valued at approximately $99,285,714. The purchase was disclosed in a filing with the SEC, which is accessible through the SEC website. Corporate insiders own 6.00% of the company’s stock.

Large investors have recently modified their holdings of the company. Paloma Partners Management Co acquired a new stake in shares of Axovant Sciences in the second quarter valued at about $356,000. Tower Research Capital LLC TRC grew its position in shares of Axovant Sciences by 1,627.0% in the second quarter. Tower Research Capital LLC TRC now owns 62,139 shares of the biotechnology company’s stock valued at $141,000 after purchasing an additional 58,541 shares during the last quarter. Connor Clark & Lunn Investment Management Ltd. grew its position in Axovant Sciences by 12.9% during the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 559,602 shares of the biotechnology company’s stock worth $1,354,000 after buying an additional 64,152 shares in the last quarter. GSA Capital Partners LLP bought a new position in Axovant Sciences during the second quarter worth about $338,000. Finally, BlackRock Inc. lifted its stake in Axovant Sciences by 13.5% during the third quarter. BlackRock Inc. now owns 1,424,710 shares of the biotechnology company’s stock worth $3,447,000 after purchasing an additional 169,918 shares during the period. 7.71% of the stock is currently owned by institutional investors.

COPYRIGHT VIOLATION WARNING: “Axovant Sciences (AXON) Shares Gap Up to $1.12” was reported by Chaffey Breeze and is the property of of Chaffey Breeze. If you are reading this news story on another domain, it was illegally copied and republished in violation of United States and international trademark & copyright law. The correct version of this news story can be read at https://www.chaffeybreeze.com/2019/01/10/axovant-sciences-axon-shares-gap-up-to-1-12.html.

About Axovant Sciences (NASDAQ:AXON)

Axovant Sciences Ltd., a clinical-stage biopharmaceutical company, engages in acquisition, development, and commercialization of therapeutics in the fields of neurology and psychiatry in the United States and the European Union. It focuses on developing AXO-Lenti-PD, an in vivo lentiviral gene therapy investigational product candidate for the one-time treatment of Parkinson's disease.

See Also: Earnings Per Share (EPS) Explained

Receive News & Ratings for Axovant Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axovant Sciences and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply